Publicaciones en colaboración con investigadores/as de Mayo Clinic (30)

2022

  1. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

2021

  1. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

    European Journal of Cancer, Vol. 152, pp. 68-77

  2. Comparison of Multimodal Therapies and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features

    JAMA Network Open, Vol. 4, Núm. 7

  3. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer[Formula presented]

    European Urology, Vol. 80, Núm. 2, pp. 142-146

  4. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

    JAMA Network Open, Vol. 4, Núm. 12, pp. E2138550

  5. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

    The Lancet Diabetes and Endocrinology, Vol. 9, Núm. 8, pp. 491-501

2019

  1. Adjuvant chemoradiation in pancreatic cancer: Impact of radiotherapy dose on survival

    BMC Cancer, Vol. 19, Núm. 1

  2. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis

    Translational Oncology, Vol. 12, Núm. 1, pp. 1-7

  3. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial

    Annals of Oncology, Vol. 30, Núm. 2, pp. 281-289

2017

  1. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase II IMvigor210 study

    Annals of Oncology, Vol. 28, Núm. 12, pp. 3044-3050

2016

  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial

    The Lancet, Vol. 387, Núm. 10027, pp. 1540-1550

2015

  1. Adjuvant chemoradiation in pancreatic cancer: A pooled analysis in elderly (≥75 years) patients

    Anticancer Research, Vol. 35, Núm. 6, pp. 3441-3446

2014

  1. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 90, Núm. 4, pp. 911-917

  2. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma

    International Journal of Radiation Oncology Biology Physics, Vol. 88, Núm. 3, pp. 618-623

2011

  1. Conclusions and Future Possibilities: IORT

    INTRAOPERATIVE IRRADIATION: TECHNIQUES AND RESULTS, SECOND EDITION

  2. Extremity and Trunk Soft-Tissue Sarcomas

    INTRAOPERATIVE IRRADIATION: TECHNIQUES AND RESULTS, SECOND EDITION (HUMANA PRESS INC), pp. 387-405

  3. Gastric Cancer

    INTRAOPERATIVE IRRADIATION: TECHNIQUES AND RESULTS, SECOND EDITION (HUMANA PRESS INC), pp. 223-248

  4. Gastric/GE Junction Cancer

    Clinical Radiation Oncology, Third Edition (Elsevier), pp. 903-933

  5. Genitourinary Cancer

    INTRAOPERATIVE IRRADIATION: TECHNIQUES AND RESULTS, SECOND EDITION (HUMANA PRESS INC), pp. 459-479

  6. Gynecologic Malignancies

    INTRAOPERATIVE IRRADIATION: TECHNIQUES AND RESULTS, SECOND EDITION (HUMANA PRESS INC), pp. 431-457